Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030417 · ClinicalTrials.gov registry record · Phase 1
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03030417: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03030417 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030417, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
Background: The new drug LMP744 (NSC 706744) damages deoxyribonucleic acid (DNA). This causes cell death. Researchers want to see if it can treat certain kinds of cancer. They want to understand how the drug works and how it affects the body. Objective: To test the safety of LMP744 and find out the dose of the drug that can be safely given to humans. Eligibility: Adults at least 18 years old who have metastatic solid tumors or lymphoma, which have progressed after other treatment. Design: Participants will be screened with: * Vital signs taken * Blood and urine tests * Heart tests * Scans or ultrasound Some participants will have a tumor sample taken 2 times. A small piece of tumor is removed by a small needle. A scan or ultrasound will guide the process. The study will be done in 28-day cycles. Each cycle, participants will get the study drug in a vein for 60 minutes once a day for 5 days. For day 1 of cycle 1, participants will be admitted to the clinic and have blood and urine taken several times. At the beginning of each cycle, participants will have a clinic visit and repeat some screening tests. They will also do this twice in the middle of cycle 1 and once in the middle of cycle 2. After participants stop taking the study drug, they will be followed for 30 days. They may give blood samples. They will be contacted by phone to see how they are doing....
Interventions
- OTHER Olanzapine
- DRUG LMP744
- OTHER Ondansetron
- OTHER Lorazepam
- OTHER Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2023-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030417
The ClinicalTrials.gov registry entry for NCT03030417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Olanzapine is the first listed.
NCT03030417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030417 about?
NCT03030417 is a clinical study titled "Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas". Background: The new drug LMP744 (NSC 706744) damages deoxyribonucleic acid (DNA). This causes cell death. Researchers want to see if it can treat certain kinds of cancer. They want to understand how the drug works and how it affects the body. Objective: To test the safety of LMP744 and find out t...
What is the current status of trial NCT03030417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2017-02-27. Estimated completion is 2023-10-12.
What interventions are being tested in trial NCT03030417?
The interventions under investigation include: Olanzapine (OTHER), LMP744 (DRUG), Ondansetron (OTHER), Lorazepam (OTHER), Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate (OTHER).
Who is sponsoring clinical trial NCT03030417?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.